Srne stock news fda approval. Between 2012 and 2021, FDA approved on average 44 d...

Jul 19, 2022 · The FDA has cleared the Investigati

The FDA will review the marketing application for Sarepta's DMD gene therapy, SRP-9001, after an advisory committee (AdCom) meeting on May 12, 2023. In 2016, Sarepta faced a controversial ...Mar 2, 2021 · Mar 2, 2021 5:18PM EST. (RTTNews) - Shares of Sorrento Therapeutics Inc. (SRNE) gained over 5% in extended trading session on Tuesday after the company FDA cleared its Investigational New Drug ... Stock Market News. SRNE. Sorrento to Host Webcast to Discuss Newly Presented Clinical Data Demonstrating Significant Improvements in Therapeutic Outcomes in 10 of 10 Patients with Poorly Controlled Rheumatoid Arthritis ... ZTlido® was approved by the FDA on February 28, 2018. For more information visit …Ardelyx ( NASDAQ: ARDX) is a good speculative biotech to look into. That's because it has been able to generate a good amount of sales with its drug ibsrela for the treatment of adults with ...Feb 21, 2023 · SAN DIEGO, Feb. 21, 2023-- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), a biopharmaceutical company dedicated to the development of life-saving therapeutics to treat cancer, intractable pain, and infectious disease, today announced that the U.S. Bankruptcy Court for the Southern District of Texas granted interim approval of Sorrento's $75 million debtor-in-possession financing from ... December 7, 2021 - 1:42 pm. A Phase 2 trial of intra-articular RTX for knee OA pain has enrolled its first two patients. The injections were well tolerated and both patients were discharged home after a brief period of observation.SRNE Sorrento today announced that it has received clearance from the FDA for its. SRNE Stock Heads Up On FDA IND Approval. Srne stock news fda approval Thursday 24 March 2022 Edit. SRNE gains on FDA news CHS rises on earnings HPQ dips on Q3 estimates and OSCR falls Seeking Alpha - Aug 31 2022 816AM Premarket Mover.Sorrento Therapeutics - We apply cutting-edge science to create innovative therapies that will improve the lives of those who suffer from cancer, intractable pain and COVID-19 FDA has new leverage over companies looking for a quicker drug approval. Congress gave the Food and Drug Administration more power to hold drugmakers accountable as part of the mammoth spending ...Find the latest TransCode Therapeutics, Inc. (RNAZ) stock quote, history, news and other vital information to help you with your stock trading and investing.Scilex Holding Company (Scilex) a subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE), is dedicated to the development and commercialization of non-opioid pain management products for ...Shares rose another 7% in early trading Thursday, to $70.14 as of 10:41 a.m. ET, before settling for a 2% gain, to $66.96. Apellis Pharmaceuticals (APLS) has scored the first-ever FDA approval for ...InvestorPlace - Stock Market News, Stock Advice & Trading Tips Pfizer (NYSE:PFE) stock and Moderna (NASDAQ:MRNA) stocks are in the news Wednes... InvestorPlace - Stock Market News, Stock Advice & Trading Tips Pfizer (NYSE:PFE) stock and...Aug 23, 2021 · This news came just a few days prior to the Pfizer-BioNTech FDA approval. With today’s update, SRNE stock has piggybacked off of last week’s momentum and continued higher on Monday. Should You Buy Vaccine Stocks Right Now? Sentiment and speculation can play big roles in the stock market. Stock Market News SRNE Sorrento Therapeutics has Received FDA Clearance to Initiate Clinical Trials with a Next Generation mRNA (STI-1557) Vaccine Against Omicron SARS-CoV-2 VirusThe U.S. Food and Drug Administration (FDA) on Wednesday approved Cidara Therapeutics Inc's drug, rezafungin, to treat a group of severe fungal infections that are most commonly faced by ...The magnitude of the difference in the treatment effect (RTX versus saline control) at 12 weeks exceeded what is traditionally considered sufficient to support regulatory approval based on greater ...Aug 17, 2020 · Palo Alto, California, April 9, 2021 — Scilex Holding (“Scilex”), an over 99% owned subsidiary of Sorrento Therapeutics (NASDAQ: SRNE, “Sorrento”), has received a supplemental new drug application (sNDA) approval from the FDA for ZTlido® to make efficacy labeling change with clinical data. July 24, 2020 - 9:00 am. SAN DIEGO and BOSTON, July 24, 2020-- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") and SmartPharm Therapeutics, Inc. ("SmartPharm") announced today the signing of a letter of intent for Sorrento to acquire SmartPharm, a gene-encoded therapeutics company developing non-viral DNA and RNA gene delivery platforms for COVID-19 and rare diseases, with broad ...Apr 25, 2022 · SAN DIEGO, April 25, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that it has received clearance from the FDA for its investigational new drug application (IND) for intravenous (IV) STI-9167 (COVISHIELD) to study the safety and pharmacokinetics in healthy volunteers. FDA has new leverage over companies looking for a quicker drug approval. Congress gave the Food and Drug Administration more power to hold drugmakers accountable as part of the mammoth spending ...Sep 18, 2020 · Now SRNE stock has become one of the most controversial, and volatile, biotech stocks in the market. From May until early August, Sorrento shares spiked from $2.60 to $19. But since then, there ... NEW YORK-- (BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for approval of PAXLOVID™ (nirmatrelvir [PF-07321332] tablets and ritonavir tablets) for patients who are at high risk for progression to severe illness from …STI-6129 is a CD38-targeting antibody drug conjugate. SRNE stock news and headlines to help you in your trading and investing decisions. Get the latest news and real-time alerts from Sorrento Therapeutics Inc. Dulan Lokuwithana SA News Editor 5 Comments. 02 2022 1202 PM ET Sorrento Therapeutics Inc.About NASDAQ:SRNE Sorrento Therapeutics (SRNE) Stock Forecast, Price & News $0.14 +0.02 (+16.26%) (As of 10/11/2023 ET) Compare Today's Range $0.13 $0.15 50-Day Range $0.09 $0.27 52 …SAN DIEGO, March 02, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that the FDA has cleared Sorrento’s internally developed anti-CD47 monoclonal antibody, STI-6643, which was discovered from Sorrento's G-MAB™ library, for an initial clinical trial.SAN DIEGO, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced the Accreditation Committee of the College of …During Q3, 224 13F filers disclosed ownership of SRNE, an increase of five filers form the prior period. In total, these filers own 162.75 million shares of SRNE stock, up from 150.44 million shares.Aug 31, 2022 · By William White, InvestorPlace Writer Aug 31, 2022, 11:20 am EDT. Sorrento Therapeutics ( SRNE) is gaining thanks to an update from the U.S. Food and Drug Administration (FDA). The FDA has ... FDA Calendar. Our FDA Calendar is designed to provide you with future catalysts across biotech & pharma companies, updated on a daily basis for all companies we cover. Utilize our filter functionality at the top of the page to screen for companies based on whatever criteria you are looking for or to see your portfolio, and also add more columns ...This news came just a few days prior to the Pfizer-BioNTech FDA approval. With today’s update, SRNE stock has piggybacked off of last week’s momentum and continued higher on Monday. Should You Buy Vaccine Stocks Right Now? Sentiment and speculation can play big roles in the stock market.Published. Jul 20, 2022 11:10AM EDT. Sorrento Therapeutics SRNE surged 10.1% on Jul 19 after the company announced that FDA cleared the investigational new drug (“IND”) application for STI ...February 16, 2023 - 2:41 pm. SAN DIEGO, Feb. 16, 2023-- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), a biopharmaceutical company dedicated to the development of life-saving therapeutics to treat cancer, intractable pain, and infectious disease, today announced that the U.S. Bankruptcy Court for the Southern District of Texas granted approval of Sorrento's employee wages motion and ...Hot Stocks: SRNE gains on FDA news, CHS rises on earnings, HPQ dips on Q3 estimates, and OSCR falls SA News Wed, Aug. 31, 2022 Sorrento stock rises 13% …Read why I think there are too many uncertainties for IBRX stock to be a Buy. ... but the FDA might balk even with a pre-approved trial design. ... On 12/12/2022, there was a news "ImmunityBio ...November 13, 2022 - 3:02 pm. ATLANTA and SAN DIEGO, Nov. 13, 2022 (GLOBE NEWSWIRE) -- Sofusa®, a wholly-owned division of Sorrento Therapeutics (Nasdaq: SRNE, “Sorrento”), today announced that it will host a virtual Key Opinion Leader (KOL) panel discussion titled “Empowering the Lymphatics: Unleashing the Potential of Biologics that Target the Immune System” to be held on Thursday ...SEMDEXA is in a pivotal Phase 3 trial for the treatment of lumbosacral radicular pain, or sciatica. ZTlido ® was approved by the FDA on February 28, 2018. For more information visit www.sorrentotherapeutics.com. Financial information. Mayo Clinic and Dr. Markovic have a financial interest in the technology referenced in this news release.The $75 Million Reason Sorrento (SRNE) Stock Is Moving TodayInvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: ra2 studio/Shutterstock Sorrento Therapeutics (NASDAQ:SRNE) stock is ...SAN DIEGO, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced receipt of approval from the Brazilian regulatory agency (ANVISA) for COVISTIX in Brazil.Elon Musk's brain implant company Neuralink announces FDA approval of in-human clinical study Published Thu, May 25 2023 8:42 PM EDT Updated Thu, May 25 2023 8:45 PM EDT Ashley Capoot @ashleycapootDec 6, 2022 · SAN DIEGO, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") has received clearance from the US FDA to initiate clinical trials with STI-1557, its next generation mRNA vaccine against SARS-CoV-2 Omicron variants. This mRNA vaccine incorporates a mutation in the furin cleavage site that prevents the S1 ... November 29, 2021 - 9:00 am. SAN DIEGO, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced the publication of a Teaser titled “Abivertinib – a Franchise Oral Therapeutic for Cancer, COVID-19 and Autoimmune Diseases” (“Abivertinib Teaser”).Furthermore, COVISTIX is still not approved in the U.S. SRNE stock has been on a volatile ride over the last year or so with its 52-week high of $17.25 and 52-week low of under $5, the levels it ...Jun 3, 2022 · SAN DIEGO, June 03, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced the first subject was dosed in a Phase I clinical study (NCT05364840) of its oral main viral protease (M pro ) inhibitor, STI-1558. The world has been experiencing repeated waves of infection of SARS-CoV-2 and its continually ... Aug 16, 2021 · Sorrento Therapeutics Inc (NASDAQ: SRNE) recently announced that it got approval from the FDA to conduct a Phase I clinical trial of its anti-CD38 DAR (Dimeric Antigen Receptor) allogenic Cell therapeutics for refractory and relapsed multiple myeloma. The proprietary anti-CD38 DAR-T Cell candidate showed robust cytotoxic activity in the pre-clinical trial. DAR-T-related product candidates are ... It was two years ago that Biogen's (BIIB 0.56%) stock soared to more than $400 on news that its Alzheimer's treatment, Aduhelm (aducanumab), had obtained accelerated approval from the Food and ...Approval of Phase 1 testing for COVI-GUARD boosted SRNE stock on Friday. Abivertinib is another potential treatment, currently in Phase 2 trials. The drug can treat the “cytokine storms” that...Mar 24, 2022 · STI-6129 is a CD38-targeting antibody drug conjugate. SRNE stock news and headlines to help you in your trading and investing decisions. Get the latest news and real-time alerts from Sorrento Therapeutics Inc. Dulan Lokuwithana SA News Editor 5 Comments. 02 2022 1202 PM ET Sorrento Therapeutics Inc. Latest SRNE News 06/05/23 9:00 AM Shanghai Escugen Biotechnology Co., Ltd., a partner of Levena Biopharma, a Sorrento Company, releases positive results from a first-in-human study of ESG401, a TROP2 Antibody Drug Conjugate in patients with locally advanced/metastatic solid tumors at the ASCO 2023 MeetingMay 17, 2022 - 9:00 am. FDA granted IND clearance for Abivertinib (Fujovee™) for the Phase 2 MAVERICK study to be conducted in participants with metastatic castrate resistant prostate cancer (mCRPC) at multiple centers in the United States.SAN DIEGO, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") has received clearance from the US FDA to initiate clinical trials with STI-1557, its next generation mRNA vaccine against SARS-CoV-2 Omicron variants. This mRNA vaccine incorporates a mutation in the furin cleavage site that prevents the S1 ...Aug 17, 2020 · Palo Alto, California, April 9, 2021 — Scilex Holding (“Scilex”), an over 99% owned subsidiary of Sorrento Therapeutics (NASDAQ: SRNE, “Sorrento”), has received a supplemental new drug application (sNDA) approval from the FDA for ZTlido® to make efficacy labeling change with clinical data. The Chinese approval covers 6 different indications including adult ulcerative colitis, ankylosing spondylitis, rheumatoid arthritis, adult and childhood Crohn’s disease, fistula Crohn’s disease, and psoriasis. Sorrento is planning to meet with FDA and EMA to discuss the data package and gain concurrence on the path forward to a BLA or MAA.ELYXYB TM is a first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults. 1 The acute migraine drug market ...srne stock news fda approval Thursday, 24 March 2022 Edit. Food and Drug Administration. Sorrento Therapeutics SRNE Receives a Buy from Dawson James TipRanks - 372022 43030 AM. ... SRNE stock news and headlines to help you in your trading and investing decisions. Get the latest news and real-time alerts from Sorrento …Sorrento Therapeutics' (SRNE) subsidiary Scilex receives Fast Track designation for its lower back pain (LBP) candidate, SP-103. Stock Up.Sorrento Therapeutics Inc (NASDAQ: SRNE) was in 13 hedge funds' portfolios at the end of the third quarter of 2020. The all time high for this statistic is 13. This means the bullish number of ...Let’s assume that Abivertinib gains FDA approval for both its cancer and Covid-19 applications. In this imaginary exercise, Sorrento would surely make a lot of money, sending SRNE stock sky high ...We have news that UPS testing STIX on behalf of FDA. Usually a testing study takes about 2 to 3 months. After the testing, it will take another 2 to 3 months to review data and make decisions. ... Point is that majority of approved tests in last two weeks was delivered to FDA for approval in Dec. ... By then there will already be 3 other ...20 votes, 17 comments. We just saw that FDA has given approval for Phase-1 mylenoma study. What is stopping them from giving approval for COVI-STIX?ELYXYB TM is a first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults. 1 The acute migraine drug market ...Sorrento Therapeutics (SRNE) Announces FDA Approval for Non-Opioid ZTlido 1.8% for PHN Pain Article Related Press Releases ( 1 ) Related Articles ( 2 ) Stock Quotes (1) FREE Breaking News Alerts ...Editor’s Note: If you or someone you know is living with an opioid addiction or another substance use disorder, know that help is available. Narcan, also known as Naloxone, is an FDA-approved medication to rapidly reverse the effects of an ...SAN DIEGO, March 02, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that it has received clearance from the FDA for its investigational new drug application (IND) for intranasal (IN) STI-9199 (COVISHIELD) to study the safety and pharmacokinetics in healthy volunteers.Oct 4, 2022 · Español. Today, the U.S. Food and Drug Administration proposed updated criteria for when foods can be labeled with the nutrient content claim “healthy” on their packaging. Sorrento Therapeutics, Inc. (NASDAQ: SRNE) (Sorrento), and its majority-owned subsidiary, Scilex Pharmaceuticals Inc. (Scilex), received approval from the U.S. Food and Drug Administration (FDA ...Apr 25, 2022 · Latest SRNE News 06/05/23 9:00 AM Shanghai Escugen Biotechnology Co., Ltd., a partner of Levena Biopharma, a Sorrento Company, releases positive results from a first-in-human study of ESG401, a TROP2 Antibody Drug Conjugate in patients with locally advanced/metastatic solid tumors at the ASCO 2023 Meeting Stock Market News. SRNE. Sorrento to Host Webcast to Discuss Newly Presented Clinical Data Demonstrating Significant Improvements in Therapeutic Outcomes in 10 of 10 Patients with Poorly Controlled Rheumatoid Arthritis ... ZTlido® was approved by the FDA on February 28, 2018. For more information visit www.sorrentotherapeutics.com. Forward ...2 Biotech Stocks Wall Street Predicts Will Rally By More Than 150%. SRNE - The Biotech industry has been instrumental in developing treatments for the coronavirus. The sector's long-term potential remains solid due to the aging populating and the rising cost of healthcare. Wall Street analysts expect biotech stocks Sorrento Therapeutics ...We would like to show you a description here but the site won’t allow us.Sorrento Therapeutics SRNE surged 10.1% on Jul 19 after the company announced that FDA cleared the investigational new drug ("IND") application for STI-1558 in patients with impaired renal and...Ardelyx ( NASDAQ: ARDX) is a good speculative biotech to look into. That's because it has been able to generate a good amount of sales with its drug ibsrela for the treatment of adults with ...Mar 24, 2022 · STI-6129 is a CD38-targeting antibody drug conjugate. SRNE stock news and headlines to help you in your trading and investing decisions. Get the latest news and real-time alerts from Sorrento Therapeutics Inc. Dulan Lokuwithana SA News Editor 5 Comments. 02 2022 1202 PM ET Sorrento Therapeutics Inc. Blogger Sentiment. The Sorrento Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not …It is available for devices and device-led combination products which are subject to review under a premarket approval application (PMA), premarket notification (510(k)), or De Novo classification ...In this Motley Fool Live video recorded on Oct. 13, Fool contributors Keith Speights and Brian Orelli discuss two upcoming U.S. Food and Drug Administration (FDA) approval decisions that investors ...May 19, 2021 - 9:30 pm. Sofusa is a drug delivery platform technology which delivers biologic therapies through the skin directly into the lymphatic system with potential to improve efficacy and safety and reduce the required dosing (as compared to traditional systemic or subcutaneous injections or infusions).Scilex Holding Company (Scilex) a subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE), is dedicated to the development and commercialization of non-opioid pain management products for ...Feb 21, 2023 · The $75 Million Reason Sorrento (SRNE) Stock Is Moving TodayInvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: ra2 studio/Shutterstock Sorrento Therapeutics (NASDAQ:SRNE) stock is ... Latest SRNE News 06/05/23 9:00 AM Shanghai Escugen Biotechnology Co., Ltd., a partner of Levena Biopharma, a Sorrento Company, releases positive results from a first-in-human study of ESG401, a TROP2 Antibody Drug Conjugate in patients with locally advanced/metastatic solid tumors at the ASCO 2023 MeetingSorrento Therapeutics Inc (NASDAQ: SRNE) was in 13 hedge funds' portfolios at the end of the third quarter of 2020. The all time high for this statistic is 13. This means the bullish number of ...Stock Market News. Earnings. Politics. Economic News. Morning Brief. Personal Finance News. ... 150%: How much Reata’s stock jumped in after-hours trading on the news of Skyclarys’ FDA approval.But the company sought FDA approval only in early 2022, and the agency rejected the application, ... For news tips, reach her at 202-967-6233. If it’s sensitive, use Signal.Feb 16, 2023 · SAN DIEGO, Feb. 16, 2023-- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), a biopharmaceutical company dedicated to the development of life-saving therapeutics to treat cancer, intractable pain, and infectious disease, today announced that the U.S. Bankruptcy Court for the Southern District of Texas granted approval of Sorrento's employee wages motion and interim approval of its cash ... Sorrento Therapeutics, Inc. (Nasdaq: SRNE) has received clearance from the US FDA to initiate clinical trials with STI-1557, its next generation mRNA vaccine against SARS-CoV-2 Omicron variants ...March 2, 2021 - 4:02 pm. FDA granted IND clearance today for the commencement of a Phase 1 safety and pharmacokinetic study for STI-2099 (COVIDROPS™) in healthy volunteers and outpatients with mild COVID-19 disease with or without a simultaneous intravenous injection of STI-2020 (COVI-AMG™).Sorrento Therapeutics - We apply cutting-edge science to create innovative therapies that will improve the lives of those who suffer from cancer, intractable pain and COVID-19 Stock Market News. SRNE. Sorrento to Host Webcast to Discuss Newly Presented Clinical Data Demonstrating Significant Improvements in Therapeutic Outcomes in 10 of 10 Patients with Poorly Controlled Rheumatoid Arthritis ... ZTlido® was approved by the FDA on February 28, 2018. For more information visit …Mar 24, 2022 · STI-6129 is a CD38-targeting antibody drug conjugate. SRNE stock news and headlines to help you in your trading and investing decisions. Get the latest news and real-time alerts from Sorrento Therapeutics Inc. Dulan Lokuwithana SA News Editor 5 Comments. 02 2022 1202 PM ET Sorrento Therapeutics Inc. Reynolds Livestock has holstein dairy calves, beef stock calves and crossbreeds available for purchase year round. The calves are between four days and two weeks old, and customers can hand pick calves from the calf barn or have them select...Looking ahead, Sorrento received court approval for “First Day” employee wages and cash management motions, which helped boost sentiment. SRNE Stock News. These motions are in focus as traders look to make sense of everything going on with SRNE stock. Sorrento recently updated a previous “FAQ” related to a dividend of Scilex Holding ...23-Aug-2021 ... When we first started following the progress of this company last year, SRNE stock was trading below $2. As of this week, shares are well above ...Sep 22, 2023 · Sorrento Therapeutics, Inc. Receives Court Approval for $75 Million Financing in Chapter 11 Case. SAN DIEGO , Feb. 21, 2023 /PRNewswire/ -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), a biopharmaceutical company dedicated to the development of life-saving therapeutics to treat cancer, ... 7 months ago - PRNewsWire. . Latest SRNE News 06/05/23 9:00 AM Shanghai Escugen Biotechnology Co.,Aug 17, 2020 · Palo Alto, California, April 9 Oct 09, 2023, 10:34 am EDT. Reprints. The Food and Drug Administration delivered a surprising rejection on Monday of an approval application from the drugmaker Alnylam Pharmaceuticals, sending ...InvestorPlace - Stock Market News, Stock Advice & Trading Tips. Sorrento Therapeutics (NASDAQ: SRNE) is down by more than 60% today following the … 31-Jul-2023 ... In 2021, ARDX stock hit over $8 when the market exp 50 See STT Report 5 Investors Betting Big on Sorrento Therapeutics (SRNE) Stock InvestorPlace - Stock Market News, Stock Advice & Trading Tips Sorrento Therapeutics (NASDAQ: SRNE) is down by more than 60% today following the company's announcement that it would file for Chapter 11 bankruptcy.Jul 20, 2022 · Sorrento Therapeutics SRNE surged 10.1% on Jul 19 after the company announced that FDA cleared the investigational new drug (“IND”) application for STI-1558 in patients with impaired renal and... InvestorPlace - Stock Market News, Stock Advice &...

Continue Reading